GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Diabetes Association  (2)
Material
Publisher
  • American Diabetes Association  (2)
Language
Years
  • 1
    Online Resource
    Online Resource
    American Diabetes Association ; 2007
    In:  Diabetes Care Vol. 30, No. 7 ( 2007-07-01), p. 1704-1708
    In: Diabetes Care, American Diabetes Association, Vol. 30, No. 7 ( 2007-07-01), p. 1704-1708
    Abstract: OBJECTIVE— We sought to assess the benefit of the Karlsburg Diabetes Management System (KADIS) in conjunction with the continuous glucose monitoring system (CGMS) in an outpatient setting. RESEARCH DESIGN AND METHODS— A multicentric trial was performed in insulin-treated outpatients (n = 49), aged 21–70 years, with a mean diabetes duration of 14.2 years. Subjects were recruited from five outpatient centers and randomized for CGMS- or CGMS/KADIS-based decision support and followed up for 3 months. After two CGMS monitorings, the outcome parameters A1C (%), mean sensor glucose of the CGMS profile (MSG) (mmol/l), and duration of hyperglycemia (h/day) were evaluated. RESULTS— In contrast with the CGMS group (0.27 ± 0.67%), mean change in A1C decreased in the CGMS/KADIS group during the follow-up (−0.34 ± 0.49%; P & lt; 0.01). MSG levels were not affected in the CGMS group (7.75 ± 1.33 vs. 8.45 ± 2.46 mmol/l) but declined in the CGMS/KADIS group (8.43 ± 1.33 vs. 7.59 ± 1.47 mmol/l; P & lt; 0.05). Net KADIS effect (−0.60 [95% CI −0.96 to − 0.25%]; P & lt; 0.01) was associated with reduced duration of hyperglycemia (4.6 vs. 1.0 h/day; P & lt; 0.01) without increasing hypoglycemia. Multiple regression revealed that the A1C outcome was dependent on KADIS-based decision support. Age, sex, physician's specialty, diabetes type, and BMI had no measurable effect. CONCLUSIONS— If physicians were supported by CGMS/KADIS in therapeutic decisions, they achieved better glycemic control for their patients compared with support by CGMS alone. KADIS is a suitable decision support tool for physicians in outpatient diabetes care and has the potential to improve evidence-based management of diabetes.
    Type of Medium: Online Resource
    ISSN: 0149-5992 , 1935-5548
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2007
    detail.hit.zdb_id: 1490520-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Diabetes Care, American Diabetes Association, Vol. 32, No. 6 ( 2009-06-01), p. 1058-1062
    Abstract: Glucose fluctuations trigger activation of oxidative stress, a main mechanism leading to secondary diabetes complications. We evaluated the relationship between glycemic variability and β-cell dysfunction. RESEARCH DESIGN AND METHODS We conducted a cross-sectional study in 59 patients with type 2 diabetes (aged 64.2 ± 8.6 years, A1C 6.5 ± 1.0%, and BMI 29.8 ± 3.8 kg/m2[mean ± SD]) using either oral hypoglycemic agents (OHAs) (n = 34) or diet alone (nonusers). As a measure of glycemic variability, the mean amplitude of glycemic excursions (MAGE) was computed from continuous glucose monitoring data recorded over 3 consecutive days. The relationships between MAGE, β-cell function, and clinical parameters were assessed by including postprandial β-cell function (PBCF) and basal β-cell function (BBCF) obtained by a model-based method from plasma C-peptide and plasma glucose during a mixed-meal test as well as homeostasis model assessment of insulin sensitivity, clinical factors, carbohydrate intake, and type of OHA. RESULTS MAGE was nonlinearly correlated with PBCF (r = 0.54, P & lt; 0.001) and with BBCF (r = 0.31, P = 0.025) in OHA users but failed to correlate with these parameters in nonusers (PBCF P = 0.21 and BBCF P = 0.07). The stepwise multiple regression analysis demonstrated that PBCF and OHA combination treatment were independent contributors to MAGE (R2 = 0.50, P & lt; 0.010), whereas insulin sensitivity, carbohydrate intake, and nonglycemic parameters failed to contribute. CONCLUSIONS PBCF appears to be an important target to reduce glucose fluctuations in OHA-treated type 2 diabetes.
    Type of Medium: Online Resource
    ISSN: 0149-5992 , 1935-5548
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2009
    detail.hit.zdb_id: 1490520-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...